FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3179681232> ?p ?o ?g. }

• W3179681232 abstract "The receptor tyrosine kinase ROR1 is a cell-surface onco-fetal protein expressed on a variety of solid tumours and haematological malignancies, which has limited expression on normal adult tissue. A functional role for ROR1 in tumorigenesis and disease progression has been demonstrated in a number of cancer indications. ROR1 is also involved in mediating drug resistance (for example to chemotherapies as well as to the targeted therapy T-DM1), activation of YAP/TAZ signalling and up-regulation of BMI-1. Consistent with this pleiotropic role, increased ROR1 expression correlates with poor clinical outcome in a number of cancer indications including triple negative breast cancer, ovarian cancer and lung adenocarcinoma. As a result, ROR1 has emerged as a highly attractive target for cancer therapy, and its limited expression on normal tissues make it particularly well suited for antibody and protein-drug conjugate (ADC and PDC) approaches. This has been fuelled by recent Phase I clinical data for the ROR1 ADC, VLS-101, in patients with advanced MCL and DLBCL and the potential of ROR1-targeting drug conjugates for the treatment of ROR1+ solid tumour indications. We report the development of novel, differentiated protein drug conjugates targeting ROR1 based on Variable New Antigen Receptor domains (VNARs). VNARs are the smallest antigen binding domain in the vertebrate kingdom and their small size and modular nature offer a number of potential benefits over full-length antibodies as the payload delivery vehicle in PDC approaches. We have applied our VNAR drug discovery platform, which includes novel linker-toxin combinations, to the development of potent and selective ROR1 targeting PDCs that are highly efficacious in ROR1+ patient derived xenograft (PDX) models of cancer. Homogenous drug conjugates were generated by Fc-fusion reformatting of ROR1 binding VNARs, and novel cleavable linker-toxin conjugates attached in a site-specific fashion. By exploiting proprietary crystal-structure information, a structure-guided approach was used to deliver VNAR-hFc drug conjugates with optimised drug-like properties. Though iterations of this approach, lead PDCs have been developed which cause potent ROR1-dependant killing of selected cancer cell-lines and elicit complete and durable regressions in PDX models of TNBC at doses that are very well tolerated. As the lead Candidate progresses toward clinical development, we anticipate that this excellent pre-clinical profile will translate to a highly differentiated product for the treatment of both solid tumor and haematological cancer indications. In addition, the flexible formatting accessible using our drug discovery platform has allowed us to readily access ROR1-targeting bi-paratopic and bi-specific therapeutic formats.Citation Format: Graham Cotton, Jennifer Thom, Paul Trumper, Stacey Bell, Mark Wappett, Caroline Barelle, Marina Kovaleva, Andrew Porter, Estelle McLean, Chiara Saladino, Aidan McCann, Aaron Cranston, Tim Harrison. Development of a next generation ROR1 targeting Protein Drug Conjugate (PDC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB096." @default.
• W3179681232 created "2021-07-19" @default.
• W3179681232 creator A5008727334 @default.
• W3179681232 creator A5011032790 @default.
• W3179681232 creator A5012106881 @default.
• W3179681232 creator A5012660136 @default.
• W3179681232 creator A5016741225 @default.
• W3179681232 creator A5023361742 @default.
• W3179681232 creator A5032281279 @default.
• W3179681232 creator A5046060433 @default.
• W3179681232 creator A5068944725 @default.
• W3179681232 creator A5076845937 @default.
• W3179681232 creator A5076903377 @default.
• W3179681232 creator A5079532494 @default.
• W3179681232 creator A5091540494 @default.
• W3179681232 date "2021-07-01" @default.
• W3179681232 modified "2023-10-18" @default.
• W3179681232 title "Abstract LB096: Development of a next generation ROR1 targeting Protein Drug Conjugate (PDC)" @default.
• W3179681232 doi "https://doi.org/10.1158/1538-7445.am2021-lb096" @default.
• W3179681232 hasPublicationYear "2021" @default.
• W3179681232 type Work @default.
• W3179681232 sameAs 3179681232 @default.
• W3179681232 citedByCount "0" @default.
• W3179681232 crossrefType "proceedings-article" @default.
• W3179681232 hasAuthorship W3179681232A5008727334 @default.
• W3179681232 hasAuthorship W3179681232A5011032790 @default.
• W3179681232 hasAuthorship W3179681232A5012106881 @default.
• W3179681232 hasAuthorship W3179681232A5012660136 @default.
• W3179681232 hasAuthorship W3179681232A5016741225 @default.
• W3179681232 hasAuthorship W3179681232A5023361742 @default.
• W3179681232 hasAuthorship W3179681232A5032281279 @default.
• W3179681232 hasAuthorship W3179681232A5046060433 @default.
• W3179681232 hasAuthorship W3179681232A5068944725 @default.
• W3179681232 hasAuthorship W3179681232A5076845937 @default.
• W3179681232 hasAuthorship W3179681232A5076903377 @default.
• W3179681232 hasAuthorship W3179681232A5079532494 @default.
• W3179681232 hasAuthorship W3179681232A5091540494 @default.
• W3179681232 hasConcept C101544691 @default.
• W3179681232 hasConcept C121608353 @default.
• W3179681232 hasConcept C126322002 @default.
• W3179681232 hasConcept C159654299 @default.
• W3179681232 hasConcept C170493617 @default.
• W3179681232 hasConcept C180361614 @default.
• W3179681232 hasConcept C203014093 @default.
• W3179681232 hasConcept C23440912 @default.
• W3179681232 hasConcept C2775960820 @default.
• W3179681232 hasConcept C2777325958 @default.
• W3179681232 hasConcept C502942594 @default.
• W3179681232 hasConcept C542903549 @default.
• W3179681232 hasConcept C71924100 @default.
• W3179681232 hasConcept C86803240 @default.
• W3179681232 hasConceptScore W3179681232C101544691 @default.
• W3179681232 hasConceptScore W3179681232C121608353 @default.
• W3179681232 hasConceptScore W3179681232C126322002 @default.
• W3179681232 hasConceptScore W3179681232C159654299 @default.
• W3179681232 hasConceptScore W3179681232C170493617 @default.
• W3179681232 hasConceptScore W3179681232C180361614 @default.
• W3179681232 hasConceptScore W3179681232C203014093 @default.
• W3179681232 hasConceptScore W3179681232C23440912 @default.
• W3179681232 hasConceptScore W3179681232C2775960820 @default.
• W3179681232 hasConceptScore W3179681232C2777325958 @default.
• W3179681232 hasConceptScore W3179681232C502942594 @default.
• W3179681232 hasConceptScore W3179681232C542903549 @default.
• W3179681232 hasConceptScore W3179681232C71924100 @default.
• W3179681232 hasConceptScore W3179681232C86803240 @default.
• W3179681232 hasLocation W31796812321 @default.
• W3179681232 hasOpenAccess W3179681232 @default.
• W3179681232 hasPrimaryLocation W31796812321 @default.
• W3179681232 hasRelatedWork W1967789049 @default.
• W3179681232 hasRelatedWork W2008017868 @default.
• W3179681232 hasRelatedWork W2012922023 @default.
• W3179681232 hasRelatedWork W2077060638 @default.
• W3179681232 hasRelatedWork W2105529073 @default.
• W3179681232 hasRelatedWork W2162585517 @default.
• W3179681232 hasRelatedWork W2166836693 @default.
• W3179681232 hasRelatedWork W2561062919 @default.
• W3179681232 hasRelatedWork W2610403267 @default.
• W3179681232 hasRelatedWork W2776647540 @default.
• W3179681232 isParatext "false" @default.
• W3179681232 isRetracted "false" @default.
• W3179681232 magId "3179681232" @default.
• W3179681232 workType "article" @default.